1492 Capital Management’s Pacira BioSciences PCRX Stock Holding History

1492 Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-79,687	Closed	-$2.44M	–	112
2023 Q3	$2.44M	Sell	79,687 -17,216	-18%	-$621K	1.57%	21
2023 Q2	$3.88M	Buy	96,903 +5,620	+6%	+$232K	2.26%	13
2023 Q1	$3.73M	Buy	91,283 +75,130	+465%	+$2.99M	2.3%	12
2022 Q4	$624K	Hold	16,153	–	–	0.4%	71
2022 Q3	$859K	Sell	16,153 -3	-0%	-$167	0.62%	54
2022 Q2	$942K	Buy	16,156 +3,546	+28%	+$232K	0.62%	56
2022 Q1	$962K	Buy	+12,610	New	+$841K	0.51%	67

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

1492 Capital Management's PCRX Position: Q4 2023 in Review

1492 Capital Management sold out of Pacira BioSciences (PCRX) in Q4 2023, closing a stake of 79,687 shares — an estimated $2.44M sold.

1492 Capital Management first reported a position in PCRX in Q1 2022 and held it in 7 quarters. The position peaked at $3.88M in Q2 2023. 261 funds tracked by Wall St. Rank hold PCRX as of Q4 2023.

1492 Capital Management reported no remaining Pacira BioSciences position as of Q4 2023 after selling out during the quarter.
1492 Capital Management sold 79,687 Pacira BioSciences shares in Q4 2023, an estimated $2.44M.
1492 Capital Management first reported a position in Pacira BioSciences in Q1 2022 and held it in 7 quarters.
1492 Capital Management's Pacira BioSciences position peaked at $3.88M in Q2 2023.
261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2023.

Based on 1492 Capital Management's 13F filing for Q4 2023, filed 12 Feb 2024.